Activated platelets may be a problem during PCI

KENGREAL® is the first and only intravenous P2Y12 receptor inhibitor

Rapidly prevent them from entering the game

KENGREAL® is the first and only intravenous P2Y12 receptor inhibitor

KENGREAL® (cangrelor) is the first and only intravenous P2Y12 receptor inhibitor

KENGREAL is a direct-acting P2Y12 receptor inhibitor specifically designed as an adjunct to PCI1,2
KENGREAL offers rapid platelet inhibition with quick offset

KENGREAL offers rapid platelet inhibition with quick offset1

  • 2-minute rapid onset, 1-hour quick offset1
  • Pharmacology: >98% inhibition of platelet aggregation in whole blood impedance aggregometry2
Learn more about the
pharmacology of KENGREAL
22% relative risk reduction in periprocedural thrombotic events in primary endpoint 38% relative risk reduction in secondary endpoint
Relative risk reduction in key endpoints

KENGREAL provided significant risk reduction vs clopidogrel in both primary (death, MI, IDR, ST) and secondary endpoints (ST) at 48 hours.1,3

The most common adverse reaction is bleeding.

Get the clinical trial data
Determine the weight-based dosing for your patients

Dosing and administration

KENGREAL is administered as a bolus and infusion after reconstitution and dilution.1

Determine the appropriate dose for your patient

Meet Kenneth and Rafael—two potential patients in whom KENGREAL may be appropriate

KENGREAL pharmacokinetics are consistent across patients and not influenced by age, sex, renal function, hepatic function, or patient presentation.

Sign up to receive information about KENGREAL
Get information

Sign up to get information about KENGREAL or request communication from a Chiesi sales representative

Request information
IMPORTANT SAFETY INFORMATION

KENGREAL® (cangrelor) for Injection is contraindicated in patients with significant active bleeding.

KENGREAL® is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to cangrelor or any component of the product.

Drugs that inhibit platelet P2Y12 function, including KENGREAL®, increase the risk of bleeding. In CHAMPION PHOENIX, bleeding events of all severities were more common with KENGREAL® than with clopidogrel. Bleeding complications with KENGREAL® were consistent across a variety of clinically important subgroups. Once KENGREAL® is discontinued, there is no antiplatelet effect after an hour.

The most common adverse reaction is bleeding.

INDICATION

KENGREAL® (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

References: 1. KENGREAL® (cangrelor) Prescribing Information. 2016. 2. Data on file. Chiesi USA, Inc. 3. Bhatt DL, Stone GW, Mahaffey KW, et al; CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368(14):1303-1313.